Category Archives: Genetic Engineering

PUBLIC RELEASE DATE:

5-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

"New Rochelle, NY, November 5, 2014The e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under controlled conditions and to study their growth and development in real-time without risk of contamination or damage. Offering the potential to test engineered tissues before human transplantation, increase the success rate of implantation, and accelerate the translation of tissue engineering methods from the lab to the clinic, the novel e-incubator is described in an article in Tissue Engineering, Part C, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Tissue Engineering website at http://online.liebertpub.com/doi/full/10.1089/ten.tec.2014.0273 until December 5, 2014."

"In the article "The e-Incubator: A Magnetic Resonance Imaging-Compatible Mini Incubator" , Shadi Othman, PhD, Karin Wartella, PhD, Vahid Khalilzad Sharghi, and Huihui Xu, PhD, University of Nebraska-Lincoln, present the results of a validation study using the device to culture tissue-engineered bone constructs for 4 weeks. The e-incubator is a standalone unit that automatically detects and regulates internal conditions such as temperature, carbon dioxide levels, and pH via a microcontroller. It performs media exchange to feed the cultures and remove waste products. The current design is compatible with MRI to monitor the constructs without removing them from the incubator. With proper adjustments, compatibility with other imaging technologies including computed tomography (CT) and optical imaging is also possible."

""Calibratable, hands-free tissue development environments are becoming increasingly important for the engineering of implantable tissues," says Tissue Engineering Co-Editor-in-Chief Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC. "In this new development, noninvasive imaging modalities are added to the spectrum of sensing and environmental capabilities that heretofore have included temperature, humidity, light, physical force, and electromagnetism. This represents a solid advance for the field.""

###

About the Journal

"Tissue Engineering is an authoritative peer-reviewed journal published online with Open Access options and in print in three parts: Part A, the flagship, published 24 times per year; Part B: Reviews, published bimonthly; and Part C: Methods, published 12 times per year. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on at the Tissue Engineering website at http://www.liebertpub.com/ten. "

About the Publisher

Read more:
New e-Incubator enables real-time imaging of bioengineered tissues in controlled unit

Phayronet ltd
Phayronet combines for medical benefits nanotechnology capabilities together with the achievements of genetic engineering. It develops the future direction of biomedical engineering developments....

By: Phayronet Ltd

Originally posted here:
Phayronet ltd - Video

Genecoin - a group of young US entrepreneurs are developing a DNA storage service that uses bitcoin technology to encrypt and store the data(Genecoin)

A group of young entrepreneurs from the US is offering to take peoples' sequenced DNA, convert it into data, and then back it up using the cryptocurrency bitcoin to keep it safe for future genetic engineering and even cloning. It's the stuff of dystopian nightmare futures with clone armies marching around demanding bitcoin for your life.

The Genecoinservice will offer users an easy-to-use DNA sampling kit which can be sent back to the startup through the mail. The firm will then perform the necessary DNA tests and then upload the genome data into a bitcoin storage network.

The creators, based in the Pacific Northwest, say that using bitcoin blockchain technology as a storage tool has great potential for the future far beyond being merely a ledger for bitcoin transactions.

"Bitcoin's core innovation is the idea of a blockchain, which is a decentralised ledger. Bitcoin isn't a currency rather it is a protocol for writing to a blockchain, and this opens the door to lots of disruptive software innovations," Genecoin's creators computer science graduates who currently want to remain anonymous told IBTimes UK.

"There are so many use cases for the blockchain, and 'currency' is only the first one. People are working on all sorts of ideas: smart property, proof of existence, assurance contracts, data storage these are all possible with bitcoin."

There are already other companies using this technique, such as Storj.io, a startup aiming to provide a super secure private cloud, but so far none focusing on genomics.

A physical representation of a Bitcoin(Reuters)

But the question is: would anyone really want to store their DNA to be used to make clones of themselves in the future, and will Bitcoin even be around for long enough to make it a reliable storage format?

"Most people think of Bitcoin as a currency but it is much more. Bitcoin stores records of transactions. Imagine if you sent Morse code messages by giving your friends money. If you're clever about it, you can encode data based on how you make those transactions," Genecoin's creators said.

The rest is here:
Genecoin: Bitcoin DNA Backup Could be Used to Forge Your Clone Army

Ebola Field Trial in Genetic Engineering Financed by Pentagon?
5 years after the fake with the swine flu: The World Health Organization WHO beats alarm: A fatal virus again threatens the world, this time it is called Ebo...

By: We Don #39;t Vaccinate!

See the rest here:
Ebola Field Trial in Genetic Engineering Financed by Pentagon? - Video

Genetic Engineering and Plastic Surgery in India
Prime Minister Modi #39;s literal interpretation of Hindu Scriptures.

By: Muneeb Haroon

Continue reading here:
Genetic Engineering and Plastic Surgery in India - Video

What is Synthetic Biology?: Engineering Life and Livelihoods
It has been referred to as extreme genetic engineering and the new frontier of biotechnology. What is "SynBio", and how will it affect the food we eat and the farmers who provide it? This short...

By: ETC Group

Follow this link:
What is Synthetic Biology?: Engineering Life and Livelihoods - Video

PUBLIC RELEASE DATE:

29-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, October 29, 2014 Cities around the world are increasingly making urban data freely available to the public. But is the content or structure of these vast data sets easy to access and of value? A new study of more than 9,000 data sets from 20 cities presents encouraging results on the quality and volume of the available data and describes the challenges and benefits of analyzing and integrating these expanding data sets, as described in an article in Big Data, the highly innovative, peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The Open Access article is available free on the Big Data website.

In the article "Structured Open Urban Data: Understanding the Landscape," Luciano Barbosa and Marcos Vieira, IBM Research, Brazil, and Kien Pham, Claudio Silva, and Juliana Freire, New York University School of Engineering and NYU Center for Urban Science and Progress, NY, present several promising findings. These include a steadily increasing volume of open urban data, the ability to integrate different data sets, and the finding that much of the available data is published in standard types of formats. The authors also discuss the main challenges that make it difficult to take full advantage of these data sources.

"Big urban data is a powerful new phenomenon that has the potential to transform everyday lives of hundreds of millions of people quickly via personal devices that integrate, filter, and create useful personalized information. This paper documents the sources and value of these data," says Big Data Editor-in-Chief Vasant Dhar, Co-Director, Center for Business Analytics, Stern School of Business, New York University.

###

About the Journal

Big Data, published quarterly in print and online, facilitates and supports the efforts of researchers, analysts, statisticians, business leaders, and policymakers to improve operations, profitability, and communications within their organizations. Spanning a broad array of disciplines focusing on novel big data technologies, policies, and innovations, the Journal brings together the community to address the challenges and discover new breakthroughs and trends living within this information. Complete tables of content and a sample issue may be viewed on the Big Data website.

About the Publisher

Read the original here:
Free urban data -- what's it good for?

PUBLIC RELEASE DATE:

30-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

Rochelle, NY, October 30, 2014Several companies are developing spacecraft designed to take ordinary citizens, not astronauts, on short trips into space. "Space tourism" and short periods of weightlessness appear to be safe for most individuals according to a series of articles on space biomedicine published in New Space, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the New Space website until November 30, 2014.

James Vanderploeg, MD, MPH and colleagues, University of Texas Medical Branch, Galveston, coauthored an article outlining the research that has been done to identify the risks and challenges involved in human commercial spaceflight. The authors describe the development of wearable biomedical monitoring equipment for spaceflight participants and of a medical and physiological database. In addition, the suthors also discuss topics such as the risk of electromagnetic interference and ionizing radiation to implanted medical devices in the article "The Human Challenges of Commercial Spaceflight: An Overview of Medical Research Conducted by the University of Texas Medical Branch Through the Federal Aviation Administration Center of Excellence."

"One of the most important areas of New Space research is to determine whether there are biomedical conditions that would disqualify ordinary citizens from a short ride to the edge of space. This first rigorous, peer-reviewed work on a broad range of volunteers indicates most people can take that brief trip," concludes Editor-in-Chief of New Space Prof. Scott Hubbard, Stanford University, in the Editorial "Space Biomedicine -- Who Can Travel to the Final Frontier?"

###

About the Journal

New Space facilitates and supports the efforts of researchers, engineers, analysts, investors, business leaders, and policymakers to capitalize on the opportunities of commercial space ventures. Spanning a broad array of topics including technological advancements, global policies, and innovative applications, the journal brings the new space community together to address the challenges and discover new breakthroughs and trends in this epoch of private and public/private space discovery. The Journal is published quarterly online with Open Access options and in print. Complete table of contents are available on the New Space website.

About the Publisher

More:
Is space tourism safe or do civilians risk health effects?

PUBLIC RELEASE DATE:

30-Oct-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, October 30, 2014Oligonucleotide-based therapeutics present unique challenges when it comes to testing their potential to cause reproductive and developmental harm. New consensus guidelines for toxicity testing that take into consideration the combined chemical and biological characteristics of these novel biopharmaceuticals are presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free on the Nucleic Acid Therapeutics website until November 30, 2014.

Joy Cavagnaro, Access BIO (Boyce, VA), Cindy Berman, Berman Consulting (Wayland, MA), Doug Kornbrust, Preclinisight (Reno, NV), Tacey White, Exponent (Philadelphia, PA), Sarah Campion, Pfizer (Groton, CT), and Scott Henry, Isis Pharmaceuticals (Carlsbad, CA), coauthored the white paper that highlights key points to consider in the design of scientifically valid and predictive toxicity studies. The authors summarize the findings of the Reproductive Subcommittee of the Oligonucleotide Safety Working Group (OSWG) in the article "Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotide-Based Therapeutics."

"I highly commend this latest white paper from the OSWG to researchers and regulators alike involved in the development and implementation of oligonucleotide or antisense based interventions," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.

###

About the Journal

Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website.

Here is the original post:
New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs

PUBLIC RELEASE DATE:

28-Oct-2014

Contact: Charli Scouller c.scouller@qmul.ac.uk 44-770-982-5741 Queen Mary, University of London @QMUL

A large analysis of over 40,000 individuals on statin treatment has identified two new genetic variants which influence how 'bad' cholesterol levels respond to statin therapy.

Statins are widely prescribed to patients and have been shown to lower bad cholesterol levels by up to 55%, making them a highly effective method of reducing risk of heart disease. However, despite this success, patient response can vary widely.

The study, led by Queen Mary University of London and published in Nature Communications, is the largest to date and involved analysing data from six randomised clinical trials and 10 observational studies to look for genetic variants influencing patients' response to statins.

Together with multiple universities around the world, the researchers validated their findings in a further 22,318 individuals and found two new common genetic variants which significantly affected the degree to which bad cholesterol was lowered during statin treatment.

Professor Mark Caulfield, Lead Author, Queen Mary University of London and the NIHR Biomedical Research Unit, comments: "This study marks an important step toward understanding how genetic variations influence statin response. However, further research is needed to find out how we can apply this in care of patients receiving statins. We must build up a bigger picture of the genetic variation that predicts statin response. Only then will we be in a position to tell whether testing for these genetic variants is of benefit to patients who take statin therapy."

The effects of all four associated genetic variants collectively account for about 5% of the variation in inter-individual response to statins. One of the identified genetic variants was shown to enhance statin response. In contrast, the second variant, thought to have a role in the uptake of statins by the liver, decreased the effects of the drug. Together, these findings may enhance our understanding of the biological mechanisms underlying bad cholesterol response to statin therapy.

Dr Michael Barnes, Co-author, Queen Mary University of London and the NIHR Biomedical Research Unit, comments: "Statins are one of the safest and most effective drugs in clinical use. Although all share a common target, some statins are more effective than others in different individuals. This study highlights a network of interacting genes which may individually or collectively influence the way that statins act in the body. In the future, this information could help us to select the most effective statin for each patient."

Read more:
Scientists find genetic variants influence a person's response to statins